Literature DB >> 15754279

Dialyzer membrane permeability and survival in hemodialysis patients.

Philippe Chauveau1, Hiep Nguyen, Christian Combe, Geneviève Chêne, Raymond Azar, Noël Cano, Bernard Canaud, Denis Fouque, Maurice Laville, Xavier Leverve, Hubert Roth, Michel Aparicio.   

Abstract

BACKGROUND: We previously showed that nutritional protein concentrations were predictive of outcome, whereas variables reflecting body composition and dialysis dose were not, in a 30-month prospective follow-up of 1,610 hemodialysis patients. Information on dialysis membrane and erythropoietin use had to be evaluated in an additional follow-up.
METHODS: A subset of 650 patients from the initial cohort of 1,610 was analyzed for survival in a 2-year extension of follow-up. Detailed data were collected: demographics; cause of renal failure; time on dialysis therapy; type of membrane; erythropoietin treatment; body mass index (BMI); predialysis albumin, prealbumin, and bicarbonate levels; and outcome. Normalized protein catabolic rate (nPCR), dialysis adequacy, and lean body mass were computed from predialysis and postdialysis urea and creatinine values.
RESULTS: Patient characteristics were age of 61 +/- 16 years, 58% men, BMI of 22.7 +/- 4.4 kg/m2 , time on dialysis therapy of 102 +/- 73 months, and 8.8% had diabetes. Dialysis parameters were duration of 247 +/- 31 minutes, Kt/V of 1.4 +/- 0.3, and nPCR of 1.2 +/- 0.3 g/kg/d. Albumin level was 3.73 +/- 0.53 g/dL (37.3 +/- 5.3 g/L), and prealbumin level was 31 +/- 8 mg/dL. The survival rate was 78.7% after 2 years. Survival was influenced by age, presence of diabetes, use of high-flux membrane, and serum albumin level, but not other variables, including Kt/V and prealbumin level. Two-year variations in values for urea, creatinine, and weight were predictive of survival in univariate, but not multivariate, analyses.
CONCLUSION: In patients on dialysis therapy for a long period, better survival was observed when high-flux dialysis membranes were used.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754279     DOI: 10.1053/j.ajkd.2004.11.014

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  26 in total

1.  Cardiorenal syndrome type 4: a review.

Authors:  Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2013-04       Impact factor: 2.041

Review 2.  Home haemodialysis and uraemic toxin removal: does a happy marriage exist?

Authors:  Raymond Vanholder; Sunny Eloot; Nathalie Neirynck; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

Review 3.  [Renal replacement therapy in the intensive care unit].

Authors:  C Morath; N Miftari; R Dikow; C Hainer; M Zeier; V Schwenger; M A Weigand
Journal:  Anaesthesist       Date:  2006-08       Impact factor: 1.041

4.  The impact of membrane permeability and dialysate purity on cardiovascular outcomes.

Authors:  Gulay Asci; Huseyin Tz; Mehmet Ozkahya; Soner Duman; Meltem Sezis Demirci; Mustafa Cirit; Savas Sipahi; Hamad Dheir; Devrim Bozkurt; Fatih Kircelli; Ebru Sevinc Ok; Sinan Erten; Muhittin Ertilav; Timur Kose; Ali Basci; Jochen G Raimann; Nathan W Levin; Ercan Ok
Journal:  J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 10.121

Review 5.  An update on uremic toxins.

Authors:  N Neirynck; R Vanholder; E Schepers; S Eloot; A Pletinck; G Glorieux
Journal:  Int Urol Nephrol       Date:  2012-08-15       Impact factor: 2.370

6.  Effect of membrane permeability on survival of hemodialysis patients.

Authors:  Francesco Locatelli; Alejandro Martin-Malo; Thierry Hannedouche; Alfredo Loureiro; Menelaos Papadimitriou; Volker Wizemann; Stefan H Jacobson; Stanislaw Czekalski; Claudio Ronco; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

7.  A randomized controlled trial of intensive periodontal therapy on metabolic and inflammatory markers in patients With ESRD: results of an exploratory study.

Authors:  Meggan M H Wehmeyer; Abhijit V Kshirsagar; Silvana P Barros; James D Beck; Kevin L Moss; John S Preisser; Steven Offenbacher
Journal:  Am J Kidney Dis       Date:  2012-12-20       Impact factor: 8.860

8.  The Relationship of Residual Renal Function with Cardiovascular Morbidity in Hemodialysis Patients and the Potential Role of Monocyte Chemoattractant Protein-1.

Authors:  Vaia D Raikou; Vasilios Kardalinos; Despina Kyriaki
Journal:  Kidney Dis (Basel)       Date:  2017-11-17

9.  The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up.

Authors:  Delong Zhao; Xuefeng Sun; Li Yao; Hongli Lin; Jijun Li; Jiuyang Zhao; Zhimin Zhang; Lide Lun; Jianrong Zhang; Mingxu Li; Qi Huang; Yang Yang; Shimin Jiang; Yong Wang; Hanyu Zhu; Xiangmei Chen
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

Review 10.  What is new in uremic toxicity?

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.